Proteome Sciences plc

Equities

PRM

GB0003104196

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 11:35:21 2024-04-25 am EDT			5-day change	1st Jan Change
3.51 ^GBX	+0.29%		+15.08%	-22.52%

Apr. 10	Proteome Sciences shares drop as revenue plunges and swings to loss	AN
Apr. 10	Proteome Sciences plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Proteome Sciences : Publication of Annual Report

June 23, 2015 at 05:20 am EDT

The Company announces that its Annual Report and Accounts for the year ended 31 December 2014, together with a notice of the Annual General Meeting and accompanying form of proxy, are available to view on the Company's website at www.proteomics.com , and will be posted to shareholders imminently.ENDS

Media enquiries:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Ian Pike, Chief Operating Officer Tel : +44 (0)1932 865065

Geoff Ellis, Finance Director

Cenkos (Nominated Adviser) Tel : +44 (0)20 7397 8900

Mark Connelly/Callum Davidson

finnCap (Joint broker)

Geoff Nash Tel : +44 (0)20 7220 0563

IKON Associates Email: adrian@ikonassociates.com

Adrian Shaw Tel: +44 (0)1483 271291

Mobile +44(0)7979 900733

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.

Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.

The Company's PS Biomarker Services™division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.

distributed by

Latest news about Proteome Sciences plc

Proteome Sciences shares drop as revenue plunges and swings to loss	Apr. 10	AN
Proteome Sciences plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Proteome Sciences Completes New US Lab Setup	Jan. 02	MT
Proteome Sciences Announces the Completion of Installation and Setup of Equipment in Its New US Laboratory in San Diego, California	Jan. 02	CI
Proteome Sciences says San Diego lab now fully operational	Jan. 02	AN
AIM WINNERS & LOSERS: Totally slides again; Proteome warns on earnings	Nov. 30	AN
Proteome Sciences shares drop as cuts annual revenue outlook	Nov. 30	AN
Proteome Sciences sees shares surge on SysQuant service launch	23-10-02	AN
Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro? Isobaric Labelling Reagents	23-10-02	CI
FTSE 100 Finishes Flat After Choppy Week	23-08-25	DJ
UK 2063 Gilt Seen Attractively Valued Ahead of Syndicated Tap	23-08-25	DJ
FTSE 100 pushes higher ahead of Fed chair speech	23-08-25	AN
AIM WINNERS & LOSERS: Panthera Resources secures litigation financing	23-08-25	AN
Proteome Sciences shares fall as swings to interim loss on costs	23-08-25	AN
Earnings Flash (PRM.L) PROTEOME SCIENCES Posts H1 Loss GBX-0.20	23-08-25	MT
Proteome Sciences plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
OnTheMarket new CFO Tom Carter starts role	23-07-04	AN
Proteome Sciences repays GBP824,400 loan in full to Vulpes	23-06-01	AN
Brand Architekts CFO to Step Down in June; Successor Named	23-05-26	MT
FTSE 100 Closes Down 0.35% After Corporate Updates; Melrose Industries Shines on Guidance Lift	23-05-17	DJ
Proteome Sciences revenue up; Mpac sees improved 2023	23-05-17	AN
Proteome Sciences expanding to US with San Diego facility	23-05-12	AN
Proteome Sciences to Set Up Facility in California, US; Shares Rise 13%	23-05-12	MT
Proteome Sciences plc Expands into United States of America	23-05-12	CI
Proteome Sciences full-year revenue rises; profit multiplies	23-04-04	AN

Chart Proteome Sciences plc

Duration

Period

More charts

Company Profile

Proteome Sciences plc is a specialist provider of contract proteomics services. The services enable drug discovery, development, and biomarker identification and employ workflows for the optimum analysis of tissues, cells, and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic, and therapeutic applications. SysQuant and TMT MS2 are its unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using super-depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents, which are sold for multiplex quantitative proteomics.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
PROTEOME SCIENCES PLC	-22.52%	12.84M
ABBOTT LABORATORIES	-2.92%	185B
MEDTRONIC PLC	-3.80%	107B
BECTON, DICKINSON AND COMPANY	-5.48%	67.55B
DEXCOM, INC.	+11.22%	54.6B
CENCORA, INC.	+16.74%	47.42B
HOYA CORPORATION	+3.86%	42.24B
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	28.24B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.42B
TERUMO CORPORATION	+12.40%	25.66B

Other Medical Equipment, Supplies & Distribution